Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Abstract
Background We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection.Methods Patients with well-differentiated or dedifferentiated liposarcoma were enrolled at four centres in France. Patients received up to three 28-day neoadjuvant treatment cycles of RG7112 1440 mg/m(2) per day for 10 days. If a patient progressed at any point after the first cycle, the lesion was resected or, if unresectable, an end-of-study biopsy was done. The primary endpoint was to assess markers of RG7112-dependent MDM2 inhibition and P53 pathway activation (P53, P21, MDM2, Ki-67, macrophage inhibitory cytokine-1 [MIC-1], and apoptosis). All analyses were per protocol. This trial is registered with EudraCT, number 2009-015522-10.Results Between June 3, and Dec 14, 2010, 20 patients were enrolled and completed pretreatment and day 8 biopsies. 18 of 20 patients had TP53 wild-type tumours and two carried missense TP53 mutations. 14 of 17 assessed patients had MDM2 gene amplification. Compared with baseline, P53 and P21 concentrations, assessed by immunohistochemistry, had increased by a median of 4·86 times (IQR 4·38-7·97; p=0·0001) and 3·48 times (2·05-4·09; p=0·0001), respectively, at day 8 (give or take 2 days). At the same timepoint, relative MDM2 mRNA expression had increased by a median of 3·03 times (1·23-4·93; p=0·003) that at baseline. The median change from baseline for Ki-67-positive tumour cells was -5·05% (IQR -12·55 to 0·05; p=0·01). Drug exposure correlated with blood concentrations of MIC-1 (p<0·0001) and haematological toxicity. One patient had a confirmed partial response and 14 had stable disease. All patients experienced at least one adverse event, mostly nausea (14 patients), vomiting (11 patients), asthenia (nine patients), diarrhoea (nine patients), and thrombocytopenia (eight patients). There were 12 serious adverse events in eight patients, the most common of which were neutropenia (six patients) and thrombocytopenia (three patients).Discussion MDM2 inhibition activates the P53 pathway and decreases cell proliferation in MDM2-amplified liposarcoma. This study suggests that it is feasible to undertake neoadjuvant biopsy-driven biomarker studies in liposarcoma.Funding F Hoffmann-La Roche.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is the first MDM2 inhibitor to enter clinical trials, where its tolerability was confirmed in liposarcoma patients and was also recently reported to have clinical efficacy in leukemia [11, 12].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [11]
In the citing paper
“In this same clinical study, increased p53, p21 and MDM2 protein expression and decreased Ki67 expression were observed in the tumor after the first 6–10 days cycle of daily RG7112 administration [11].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [11]
In the citing paper
“Some severe adverse effects were reported in a phase I trial of RG7112 in patients: neutropenia in six out of 20 patients and thrombocytopenia in three out of 20 patients [11].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [11]
In the citing paper
“In the clinic, RG7112 treatment of MDM2-amplified liposarcoma patients resulted in a stable disease (14 out of 20 patients) or a partial response (1 out of 20 patients) [11].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [11]
In the citing paper
“Although the levels of p53 and downstream p21 in patients with liposarcoma treated with this drug were significantly increased, one case of PR and 14 cases of SD were found in 17 assessable patients. However, at least one adverse reaction occurred in all patients, including 12 serious adverse reactions, including neutropenia and thrombocytopenia in eight patients [25].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [25]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citationPathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K., & Mertens, F. (2002) · Lund University Publications (Lund University) · Cited by 4,467
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Coindre, J.-M., Terrier, P., Guillou, L., Le Doussal, V., Collin, F., Ranch�re, D., Sastre, X., Vilain, M.-O., Bonichon, F., & N'Guyen Bui, B. (2001) · Cancer · doi:10.1002/1097-0142(20010515)91:10<1914::aid-cncr1214>3.0.co;2-3 · Cited by 740
Cited by
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
“Clinical trials of MDM2 inhibitor RG7112 encountered toxicities consistent with the effects of p53 activation in the hematopoietic system, suggesting that the observations in mice may also be applicable to humans (Ray-Coquard et al. 2012).”
BackgroundSmall-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
“Early trials for RG7112 have shown pharmacodynamic activity, including 3- to 5-fold increases in levels of p53 and p53 target genes (Ray-Coquard et al., 2012), and potential therapeutic activity in acute leukemia (M.”
BackgroundTumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 697
Metadata
- Authors
- Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., Geho, D., Middleton, S. A., Vassilev, L. T., Nichols, G. L., & Bui, B. N.
- Affiliations
- Lyon 1 Université (FR)
- Inserm (FR)
- Centre Oscar Lambret (FR)
- Institut Bergonié (FR)
- Corresponding author
- Ray-Coquard, Isabelle
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 13
- Issue
- 11
- Pages
- 1133-1140
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2155906069
- Cited by
- 571
- References
- 34
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 26 · 2023: 38 · 2022: 29 · 2021: 45 · 2020: 41 · 2019: 41 · 2018: 41 · 2017: 46 · 2016: 60 · 2015: 64 · 2014: 61 · 2013: 32 · 2012: 1
- FWCI
- 41.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eurosarc (FP7-278472)
- LYRIC (grant INCA_4664)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- RG7112, MDM2 inhibitors, liposarcoma, dedifferentiated liposarcoma, well-differentiated liposarcoma, MDM2 amplification, p53 pathway, p21, Ki-67, MIC-1, apoptosis, neoadjuvant therapy, proof of mechanism, TP53
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Cell Differentiation, Female, Humans, Liposarcoma, Male, Middle Aged, Mutation, Tumor Suppressor Protein p53, Apoptosis, Disease-Free Survival, Cell Proliferation, Proto-Oncogene Proteins c-mdm2, Growth Differentiation Factor 15, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70474-6
- The paper
- Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., Geho, D., Middleton, S. A., Vassilev, L. T., Nichols, G. L., & Bui, B. N. (2012). Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70474-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.